News

Dr. Mark Filiaggi, Department of Applied Oral Sciences, along with co-investigators Dr. Bob Abraham and PhD student Arash Momeni, has been awarded $49,500 of Early Stage Commercialization Funding from Innovacorp for "Commercialization of CaP Liquid Embolic System."

This funding will help develop and commercialize a liquid embolic material. This new material is designed to be injected into blood vessels where it will form a solid or gel-like embolus (blockage).

Embolization is commonly used to stop uncontrolled bleeding or to block blood flow to a target tissue, such as a tumour. The researchers believe this new material will have several advantages over existing liquid embolics and intend to initially focus its use on the treatment of tumours.